Recent years have seen a change in the clinical approach to T2D, novel approaches to the delivery of drugs have appeared, and the use of GLP-1 analogues and SGLT2-inhibitors have demonstrated that new treatment alternatives can still influence the overall care of patients with T2D and that the assessment of new treatment targets is still important [40,41]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.